valsartan/hydrochlorothiazide ratiopharm 160 mg / 12.5 mg tabletti, kalvopäällysteinen
ratiopharm gmbh - valsartanum,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 160 mg / 12.5 mg - valsartaani ja diureetit
lisinopril/hydrochlorothiazide orion 20 mg / 12.5 mg tabletti
orion corporation - hydrochlorothiazide, lisinopril dihydrate - tabletti - 20 mg / 12.5 mg - lisinopriili ja diureetit
valsartan/hydrochlorothiazide amneal 80 mg / 12.5 mg tabletti, kalvopäällysteinen
amneal pharma europe limited - hydrochlorothiazidum,valsartanum - tabletti, kalvopäällysteinen - 80 mg / 12.5 mg - valsartaani ja diureetit
valsartan/hydrochlorothiazide teva 160 mg / 12.5 mg tabletti, kalvopäällysteinen
teva sweden ab - hydrochlorothiazidum,valsartanum - tabletti, kalvopäällysteinen - 160 mg / 12.5 mg - valsartaani ja diureetit
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
olmesartan medoxomil/hydrochlorothiazide krka 20 mg / 12.5 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - hydrochlorothiazide, olmesartan medoxomil - tabletti, kalvopäällysteinen - 20 mg / 12.5 mg - olmesartaanimedoksomiili ja diureetit
olmesartan medoxomil/hydrochlorothiazide krka 20 mg / 25 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - hydrochlorothiazide, olmesartan medoxomil - tabletti, kalvopäällysteinen - 20 mg / 25 mg - olmesartaanimedoksomiili ja diureetit
olmesartan medoxomil/hydrochlorothiazide krka 40 mg / 12.5 mg tabletti, kalvopäällysteinen
krka, d.d., novo mesto - hydrochlorothiazide, olmesartan medoxomil - tabletti, kalvopäällysteinen - 40 mg / 12.5 mg - olmesartaanimedoksomiili ja diureetit